CommentaryThe challenge of defining mesenchymal stromal cell potency assays and their potential use as release criteria
References (10)
- et al.
Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement
Cytotherapy
(2006) - et al.
Standardization of Good Manufacturing Practice–compliant production of bone marrow–derived human mesenchymal stromal cells for immunotherapeutic applications
Cytotherapy
(2015) - et al.
Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease
Biol Blood Marrow Transplant
(2009) - et al.
A reproducible immunopotency assay to measure mesenchymal stromal cell–mediated T-cell suppression
Cytotherapy
(2015) The mesenchymal stromal cells dilemma–does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road?
Cytotherapy
(2013)
There are more references available in the full text version of this article.
Cited by (0)
Copyright © 2015 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.